Ibogaine
anti-addictive
What it isIboga alkaloid with NMDA antagonism, kappa agonism and SERT inhibition; unapproved treatment for opioid dependence.
Why this oneA single dose is reported to interrupt withdrawal and craving, which no approved agent does.
What limits it⚑ Fatal arrhythmias from QT prolongation have occurred in unmonitored clinic settings. Not approved anywhere in the US.
FDA-approved for
- opioid use disorder (investigational, non-US)
Off-label
- opioid use disorder (offered in clinics outside the US; cardiac deaths reported)
NO BOXED WARNINGS
Principal risk⚑ Fatal arrhythmias from QT prolongation have occurred in unmonitored clinic settings
Classes and tags
Clinical profile
Active metabolites
Mechanism of action: Ibogaine ballicule
